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Abstract
Aims/hypothesis The study aimed to compare the effects of
a 2 year intervention with a low-fat diet (LFD) or a low-
carbohydrate diet (LCD), based on four group meetings to
achieve compliance.
Methods This was a prospective randomised parallel trial
involving 61 adults with type 2 diabetes consecutively
recruited in primary care and randomised by drawing ballots.
Patients that did not speak Swedish could not be recruited.
The primary outcomes in this non-blinded study were weight
and HbA1c. Patients on the LFD aimed for 55–60 energy per
cent (E%) and those on LCD for 20 E% from carbohydrate.
Results The mean BMI and HbA1c of the participants were
32.7±5.4 kg/m2 and 57.0±9.2 mmol/mol, respectively. No
patients were lost to follow-up. Weight loss did not differ
between groups and was maximal at 6 months: LFD −3.99±
4.1 kg (n031); LCD −4.31±3.6 kg (n030); p<0.001 within
groups. At 24 months, patients on the LFD had lost −2.97±
4.9 kg and those on LCD −2.34±5.1 kg compared with
baseline (p00.002 and p00.020 within groups, respectively).
HbA1c fell in the LCD group only (LCD at 6 months −4.8±
8.3 mmol/mol, p00.004, at 12 months −2.2±7.7 mmol/mol,
p00.12; LFD at 6 months −0.9±8.8 mmol/mol, p00.56). At
6 months, HDL-cholesterol had increased with the LCD (from
1.13±0.33 mmol/l to 1.25±0.47 mmol/l, p00.018) while
LDL-cholesterol did not differ between groups. Insulin doses
were reduced in the LCD group (0 months, LCD 42±65 E,
LFD 39±51 E; 6 months, LCD 30±47 E, LFD 38±48 E;
p00.046 for between-group change).
Conclusions/interpretation Weight changes did not differ
between the diet groups, while insulin doses were reduced
significantly more with the LCD at 6 months, when com-
pliance was good. Thus, aiming for 20% of energy intake
from carbohydrates is safe with respect to cardiovascular
risk compared with the traditional LFD and this approach
could constitute a treatment alternative.
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The prevalence of type 2 diabetes is increasing worldwide,
and this is likely to be a consequence of the increasing
prevalence of obesity. Weight loss in obesity generally leads
to improvement in cardiovascular risk factors and glycaemic
control [1, 2]. However, few randomised studies have spe-
cifically targeted type 2 diabetes to compare the effect of
different diets in this respect. Traditionally, a low-fat diet
(LFD) has been recommended [3] to patients with type 2
diabetes as a means to lose weight and, in particular, a low
intake of saturated fat has been advocated [4, 5]. Interest-
ingly, in a randomised 2 year study from Israel that achieved
good compliance, a high-fat diet was shown to induce better
weight reduction and improved blood lipid levels than a
traditional LFD in obese participants, while the subgroup
of patients with diabetes who were randomised to the high-
fat diet exhibited the largest reduction in HbA1c levels [6].
From a physiological point of view it could be argued
that carbohydrate should be avoided to achieve good gly-
caemic control in type 2 diabetes, as a typical feature of type
2 diabetes is the combination of reduced insulin sensitivity
and the failure of beta cells to provide adequate amounts of
insulin to handle glucose derived from carbohydrate in the
diet. However, when the macronutrient composition is
changed in a diet by reducing carbohydrate, the energy from
this source is primarily replaced by that from fat, as a high
energy intake from protein is hard to achieve in the long
term. Thus, a low-carbohydrate diet (LCD) is quite similar
to one with a high intake of fat, which has traditionally been
linked with increased risk for arteriosclerosis, particularly
when large amounts of saturated fat are consumed. However,
recent data have challenged the concept of the risks with a
high-fat diet. In a Swedish observational study in 28,000
middle-aged individuals, neither a high fat intake nor an intake
of large amounts of saturated fat (22 E%) was linked with an
increased risk for cardiovascular disease [7, 8].
Most earlier studies examining high-fat diets in patients
with type 2 diabetes have had limitations, such as a high
dropout frequency [9–12], lack of randomisation [13–15], or
a maximum duration of 12 months [11, 12, 16]. Another
problem for the clinical feasibility of studies involving
patients with type 2 diabetes has been the scale of the
resources necessary to achieve compliance with the tested
diets; typically, numerous individual meetings with trained
dietitians are held during the studies [11, 16, 17]. If these
measures were to become part of routine healthcare for such
a common disease, there would be considerable economic
implications for the medical provider.
We performed a randomised study in patients with type 2
diabetes to compare glycaemic control, weight loss and
cardiovascular risk factors based on the advice of a low-
carbohydrate or a traditional LFD. In contrast to most
previous studies, the patients randomised to the LCD were
not asked to avoid saturated fat. The interventions were
based on four group meetings with a duration of 60 min
each for the first year; no further group meetings during the
remaining 12 months were held. Our hypothesis was that the
high-fat diet would improve glycaemic control more effi-
ciently than the traditional LFD in a study in which few
resources were allocated for achieving compliance, so that
clinical use of the protocol would be realistic for many
providers of care.
Methods
The study was conducted in two primary healthcare centres
in the cities of Motala and Borensberg, located in southeast
Sweden. Patients who fulfilled the criteria for participation
were contacted individually by one of three study nurses.
The nurses had also been responsible for the care of these
potential participants ahead of the study start. The inclusion
criteria were a diagnosis of type 2 diabetes treated with diet
with or without additional oral glucose-lowering medica-
tion, incretin-based therapy or insulin. There were no weight
or age exclusion criteria, but patients who had difficulties
understanding the Swedish language, were suffering from
severe mental disease or malignant disease, or who were
abusing drugs could not participate in the study.
The patients were randomised to either an LCD or a
traditional LFD, both with an energy content of 6,694 kJ/day
(1,600 kcal/day) for women or 7,531 kJ/day (1,800 kcal/day)
for men. Randomisation was not stratified and was based on
drawing blinded ballots. The LCD had an energy content
where 50 energy per cent (E%) was from fat, 20 E% was from
carbohydrate and 30 E% was from protein. The LFD had a
nutrient composition that was similar to that traditionally
recommended for the treatment of type 2 diabetes in Sweden,
with 30 E% from fat (less than 10 E% from saturated fat), 55–
60 E% from carbohydrate and 10–15 E% from protein.
Group information was used to inform the randomised
patients about which food items to choose from, and this
was given at baseline, and 2, 6 and 12 months by two
different physicians. One dedicated dietitian provided the
participants from both groups with suitable recipes at each
group meeting, and was also available consecutively during
the trial for questions from the participants. However, all the
information necessary was provided at the group informa-
tion meetings, and thus no individual meetings with the
dietitian were scheduled as part of the general protocol.
Menus for 1 week were provided to the participants as meal
suggestions by the dietitian. Each patient had the same
dedicated nurse during the whole study period and the
nurses could also provide information about food to the
patients during regular consultations. The patients were
Diabetologia (2012) 55:2118–2127 2119
recommended to check plasma glucose levels before and
after meals after initiation of the study to allow for proper
adjustment of medication to avoid hypoglycaemia. No in-
formation was given to change the level of physical activity.
As the duration of the trial was 2 years, and because indi-
viduals with high risk for cardiovascular events were
recruited, it was judged to be unethical not to be allowed
to adjust medication to avoid cardiovascular disease in the
study. The physician responsible for each patient at the
primary healthcare centre was thus allowed to adjust hypo-
lipidaemic and antihypertensive medications consecutively
in the trial.
Investigations of anthropometrics and laboratory tests
were performed at baseline and at 6, 12 and 24 months,
and patients were also asked to fill out questionnaires of
wellbeing at these time points. Diet records were also per-
formed at these four visits, with one additional recording at
3 months. The diet records were conducted during 3 con-
secutive days, of which 1 day was a Saturday or a Sunday.
The participants were provided with dedicated scales and
notebooks from the organisers with which to weigh and
record all food items that were consumed during these periods
(food frequency questionnaires were not used). Sagittal ab-
dominal diameter was measured with a sliding beam set
square as the highest abdominal level above the upper surface
of the corresponding bed. The laboratory tests were analysed
at the Department of Clinical Chemistry at the University
Hospital of Linköping as part of clinical routine analyses,
and fasting LDL-cholesterol was thus calculated using the
Friedewald formula.
Statistics Statistical calculations were made using PASW
18.0 software (SPSS, Chicago, IL, USA). Linear correlations
were calculated as stated in the text. Comparisons within and
between groups were made with Student’s paired and un-
paired two-tailed t tests or as stated in the results section.
The mean (SD) is given unless otherwise stated. Statistical
significance was considered to be present at the 5% level
(p≤0.05). ANOVAwith repeated measures was used for cal-
culations of the changes during the total duration of the study.
The size of the study was based on an earlier 6 month
pilot study of 28 participants with type 2 diabetes who were
randomised to the same diets as in the study presented in
this paper. Twenty individuals completed the pilot study and
both diet groups achieved similar weight reductions, while
HbA1c levels tended to be lowered in the low-carbohydrate
group only, without taking change in medication into ac-
count (low carbohydrate, p00.068; low-fat group, p00.8).
Based on these results, the study sample was increased to at
least 30 individuals in each group in the present study. None
of the participants in the pilot study participated in the trial
presented in this paper. The study duration of 24 months was
requested by the Regional Ethics Committee of Linköping.
Ethical approval The study was approved by the Regional
Ethics Committee of Linköping and performed in accor-
dance with the Declaration of Helsinki. Written informed
consent was obtained from all participating individuals. The
study was registered with trial number NCT01005498 at
ClinicalTrials.gov.
Results
Total study population The study nurses invited 72 consecu-
tive patients to participate in the study from the autumn of 2008
to the start of the clinical trial in March 2009. Ten patients
declined because they judged the study to be too time-
consuming and one patient believed that a high-fat diet might
be hazardous. The remaining 61 patients entered the study, but
three in the LFD group and four in the LCD group expressed
that they had severe difficulty following the prescribed diets
and were not willing to participate in the group meetings. Data
on the main outcomes from these seven patients were used in
statistical analyses according to intention-to-treat analysis
(Table 1; see also Fig. 1 for flow diagram). In the low-fat
group, the mean age was 62.7±11 years, there were 13 men
and 18 women and the mean duration of known diabetes was
8.8±6.2 years. Corresponding figures for the low-carbohydrate
group were 61.2±9.5 years, 14 men and 16 women and a
duration of known diabetes of 9.8±5.5 years. Age, sex distri-
bution and known duration of diabetes did not differ between
the groups (all p>0.5). At baseline, two patients in the low-fat
group and two in the low-carbohydrate groupwere treatedwith
diet only, 13 in the low-fat group and 15 in the low-
carbohydrate group were using oral glucose-lowering medica-
tion only, and 11 in the low-fat group and 10 in the low-
carbohydrate group were treated with a combination of insulin
and oral medication. At 24 months, 14 individuals (four in the
LFD group and ten in the LCD group) did not provide diet
records, but data on the main outcomes were used in calcula-
tions. The dietitian had individual consultations with four
patients in the low-carbohydrate group and three patients in
the low-fat group; information was otherwise only provided
during the group meetings. These individual contacts all took
part during the first 12 months of the study. Table 1 shows
anthropometrics, laboratory variables and medication from
baseline throughout the study. The recorded intake of energy
from fat and carbohydrate differed between the groups
(Table 2).
There was no difference in weight reduction between the
groups at 6 months (LFD group −4.0±4.1 kg; LCD group
−4.3±3.6 kg; p00.75 for difference in change between
groups and p<0.001 within either group; Table 1 and
Fig. 2). There were also no statistically significant differ-
ences in weight reduction between groups after adjustment
for baseline carbohydrate or fat intake (all p>0.5).
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A significant reduction in HbA1c was seen at 6 months in
the low-carbohydrate group only (Table 1). However, HbA1c
levels gradually returned to baseline levels after 6 months as
shown in Fig. 3 and Table 1. The change in HbA1c level at
6 months compared with baseline was not statistically signif-
icant between the groups (p00.089). Reductions in oral med-
ication and insulin dose were made consecutively to avoid
hypoglycaemia, and the reduction in insulin was statistically
significant only in the low-carbohydrate group at 6 months
(Table 1). This change in the average insulin dose was
statistically significant between the two groups at 6 months
(p00.046).
There were no significant differences between groups
regarding office blood pressure levels in the study (Table 1).
At 6 months, four patients in the LCD group and one patient
in the LFD group had started on treatment with statins or
had their former dose increased (see also Table 1).
Corresponding figures for these medical adjustments during
the entire study period were nine patients in the LCD group
and seven patients receiving the LFD. By the end of the
trial, 54 of 61 patients received lipid-lowering medication.
At 6 months, the low-carbohydrate group showed
significantly increased levels of HDL-cholesterol (Table 1;
p00.018 for change within group, p00.077 for change
between groups). No patient suffered cardiovascular disease
or other serious adverse events during the study.
The results of the dietary records are shown in Table 2.
During the first 6 months, adherence to the proposed diet
was comparatively good in both groups as judged by mean
values of macronutrient intake (Table 2). The low-fat group
did not significantly change the macronutrient composition
during the study, while there was an increase in energy from
fat in those randomised to LCD (Table 2). Despite reduction
of energy intake, total intake of fat showed no reduction in
the low-carbohydrate group, which was in contrast to the
low-fat group (Table 2). The percentage of energy intake
from saturated fat increased in the low-carbohydrate group
throughout the whole study, but there were no differences
between the groups regarding energy intake, according to
the diet records (Table 2).
Completers analysis Additional analyses were made
according to compliance with energy intake. Table 3 shows
results for only those patients who consumed ≤6,694 kJ/day
Assessed for eligibility (n=72)
Excluded  (n=11) 
• Did not meet inclusion criteria (n=0)
• Declined to participate (n=11) 
• Other reasons (n=0) 
Analysed (n=31)
• Excluded from analysis of main outcome 
(n=0)
• Lack of data on food registration at 24 months 
(n=4)
Lost to follow-up (n=0)
• Discontinued intervention (did not attend 
group meetings, n=3)
Allocated to intervention LFD (n=31) 
• Received allocated intervention (n=31)
• Did not receive allocated intervention (n=0)
Lost to follow-up (n=0)
• Discontinued intervention (did not attend 
group meetings, n=4)
Allocated to intervention LCD (n=30)
• Received allocated intervention (n=30)
• Did not receive allocated intervention (n=0)
Analysed (n=30)
• Excluded from analysis of main outcome  
(n=0)







Fig. 1 Flow diagram of the
study
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(1,600 kcal/day) for women or ≤7,531 kJ/day (1,800 kcal/
day) for men according to the last diet record at 24 months;
it includes 17 patients in the low-fat group and 18 patients in
the low-carbohydrate group. At 24 months the patients
randomised to the LFD weighed 3.1±4.3 kg less than at
baseline and the corresponding figure for the low-
carbohydrate group was 3.5±4.0 kg. This suggests that, in
particular, the high-fat group had lower compliance at this
time point, which affected weight gain in the total LCD-cohort
(i.e. −3.5±4.0 kg in completers compared with −2.3±5.1 kg in
the total cohort).While sagittal abdominal diameter was stable
in the low-fat group, this was reduced by 2 cm in the low-
carbohydrate group. However, the low-fat group with energy
compliance had reduced systolic and diastolic blood pressure,
effects lacking in those randomised to the high-fat diet
(Table 3). A second completers analysis based on compliance
with fat intake is available in the electronic supplementary
material (ESM; compliance defined as: ≤35 E% from fat in the
low-fat group, n020, or ≥45 E% from fat for the low-
carbohydrate group, n012, χ2 between groups for compliance
with intake of fat p00.06). Similar results to those in the
completers analysis according to energy intake were found
Table 2 Dietary outcomes at 0, 6, 12 and 24 months after the initiation in patients with type 2 diabetes randomised to the LFD or LCD
Variable 0 months 3–6 months 12 months 24 months p valueb p valuec
n061 n055 n042 n047
Value Value p valuea Value p valuea Value p valuea
Energy intake (kJ)
LFD 7,569±2,063 6,498±1,787 0.005 6,619±2,075 0.075 6,104±1,891 0.002 0.010 0.065
LCD 7,071±1,782 5,791±1,531 <0.001 6,017±2,075 0.037 5,234±1,799 <0.001 <0.001
Carbohydrate energy (%)
LFD 48±6 49±6 0.88 47±6 0.38 47±7 0.31 0.28 <0.001
LCD 41±11e 25±8d <0.001 27±8d <0.001 31±6d <0.001 <0.001
Fat energy (%)
LFD 32±5 29±5 0.12 31±6 0.96 31±7 0.87 0.28 <0.001
LCD 39±7e 49±7d <0.001 47±6d <0.001 44±5d <0.001 <0.001
Protein energy (%)
LFD 19±3 21±3 0.012 20±3 0.044 20±2 0.045 0.037 0.009
LCD 19±3 24±3d <0.001 23±5d 0.002 24±4d <0.001 <0.001
Alcohol energy (%)
LFD 1±2 2±3 0.23 2±3 0.36 2±3 0.27 0.72 0.49
LCD 2±4 2±4 0.83 2±3 0.037 2±4 0.79 0.018
Total fat (g)
LFD 66±23 53±20 0.014 56±23 0.27 52±22 0.007 0.11 0.008
LCD 74±23 78±24d 0.081 77±29 0.22 63±24 0.17 0.10
Saturated fat energy (%)
LFD 13±3 11±2 0.090 12±3 0.96 13±3 0.61 0.20 <0.001
LCD 16±4 20±4d <0.001 20±4d 0.008 19±2d <0.001 <0.001
Unsaturated fat energy (%)
LFD 12±2 11±2 0.20 11±2 0.71 11±3 0.50 0.80 <0.001
LCD 14±3 18±3d <0.001 17±3d <0.001 16±3d <0.001 <0.001
Polyunsaturated fat energy (%)
LFD 5±2 5±2 0.92 5±2 0.97 5±2 0.58 0.76 0.001
LCD 6±3 8±2d <0.001 8±2d 0.006 6±2 0.044 0.002
Data are given for all participants who provided complete diet records
a Compared with baseline
b For change over all time points
c For change over all time points (between groups)
d Denotes statistically significant difference between changes in the two groups
e Denotes statistically significant difference between groups at baseline
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in this post-hoc calculation for sagittal abdominal diameter
and blood pressure. HDL-cholesterol increased from 1.11±
0.36 to 1.46±0.59 mmol/l (p00.001 for all time points) in
those compliant with the LCD according to fat intake, while
corresponding figures for the LFD were 1.05±0.26 mmol/l at
baseline to 1.17±0.25 mmol/l at 24 months (p00.006 within
group and p00.016 for change between groups).
Discussion
Our study did not confirm the finding that weight reduction
is more efficient in individuals following an LCD than in
those following an LFD, as has been found in some previous
trials [6, 9, 12, 18–20]. An important difference in our study
compared with these earlier studies [6, 9, 12, 18–20] was
that we used comparatively fewer resources to achieve com-
pliance. In our study, only four group meetings were offered
during the first 12 months of the trial. The rationale for this
design was to make the results more applicable to regular
clinic care in which educational activities such as group
meetings can be offered as a means to improve glycaemic
control. No patients were lost to follow-up and data on
glycaemic control were complete at 24 months, while data
on weight were lacking for only one participant at this time
point. This outcome of our study left minimal room for the
selection of participants, who did indeed find either of the
diets suitable, to affect the main outcomes. Our findings
indicate that if patients are randomised to an LCD compared
with an LFD with resources used to achieve changes in diet
composition that are readily available for many providers of
care, both diets induce similar weight reductions. This was
also in line with the finding that both groups reported similar
energy intake during the study. Westman et al have reported
more efficient weight reduction with an LCD after 6 months
when compared with an LFD [9]. In that study, diet infor-
mation was facilitated, compared with our design, by lack of
energy restriction in the low-carbohydrate group. This could
have affected the more beneficial findings compared with
our study regarding weight loss. Also, Westman et al had a
total of 18 group meetings during their 6 month study, and
this could have affected the outcome. Information on in-
creased exercise was also part of their lifestyle change
programme, but was not included in ours. Specifically, we
aimed to study the effects of macronutrient composition on
glycaemic control and cardiovascular risk factors, which
was why we aimed to achieve no differences in energy
intake in the information we gave to the participants. Inter-
estingly, we did find an increase in HDL-cholesterol after
6 months and a specific reduction in HbA1c levels in the
low-carbohydrate group only, which suggests that these
effects are dependent on macronutrient composition per se;
this is in line with the findings of Westman et al [9].
We also acknowledge that we might have achieved better
weight reduction if a design similar to that used in ‘Weight
Watchers’ programmes had been incorporated. For regular
care provided by the Swedish tax-based system, incentives
used in Weight Watchers, such as public display of the body
weight results of the participants, would not be feasible for
general use in clinic care because of patient privacy. Also,
one should keep in mind that there is selection and incentive
in such commercially run programmes, as participants are
willing to pay to participate. However, effective weight loss
in a Weight Watchers group was recently shown in a study
even when the cost for participation was reimbursed by the
study organisers [21].
Fig. 2 Comparison of weight reduction with an LCD, aiming to
achieve 20 E% from carbohydrate (squares), and an LFD (circles),
aiming for 55–60 E% from carbohydrates, during 2 years in patients
with type 2 diabetes. The weight reduction did not differ between the
groups (p00.33 for all time points)
Fig. 3 Comparison of the reduction in HbA1c levels following an LCD
with the aim of achieving 20 E% from carbohydrate (squares), and an
LFD (circles), aiming for 55–60 E% from carbohydrate, over 2 years in
patients with type 2 diabetes. The reduction in HbA1c level was
statistically significant within the low-carbohydrate group (p00.005
for all time points), but did not differ between the groups when
compared at all time points (p00.76). To convert values for HbA1c in
mmol/mol into %, divide by 10.929 and add 2.15
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Although patients in our study who had been randomised
to the low-carbohydrate group reported a lower intake of
carbohydrates at baseline compared with the low-fat group,
this was unrelated to weight changes in statistical analyses.
In retrospect, this group difference in reported intake of
macronutrients between the groups might have been a
consequence of the participants being informed of the ran-
domisation results before the diet record at baseline was
performed. Consequently, some participants may have ad-
justed their diet to make it similar to that to which they had
been allocated, ahead of the first group information meeting.
Unfortunately the baseline difference was not elucidated
Table 3 Completers analysis of anthropometrics, metabolic outcomes
and medication in patients with type 2 diabetes randomised to the LFD
or LCD who were compliant with energy restriction <6,694 kJ/day
(1,600 kcal/day) for women or <7,531 kJ/day (1,800 kcal/day) for men
according to diet records at the 24 month registration
Variable Diet Time point (months) p valuec p valued
0 6 12 24
Value p valuea Value p valueb Value p valueb Value p valueb
Weight (kg) LFD 90.6±19 0.66 86.7±19 <0.001 88.0±19 <0.001 87.5±19 0.008 <0.001 0.75
LCD 88.0±16 83.4±15 <0.001 85.6±15 <0.001 84.4±16 0.002 <0.001
BMI (kg/m2) LFD 31.6±5 0.71 30.2±5 <0.001 30.7±5 <0.001 30.5±5 0.005 <0.001 0.74
LCD 31.0±4.5 29.4±4.1 <0.001 30.0±4.5 0.001 29.8±4.5 0.002 <0.001
Waist (cm) LFD 107±13 0.31 102±15 <0.001 103±16 <0.001 103±16 0.004 <0.001 0.57
LCD 103±12 100±10 0.004 100±10 0.072 100±12 0.003 0.023
Sagittal abdominal
diameter (cm)
LFD 26±5 0.97 25±3 0.58 26±3 0.68 26±4 0.49 0.46 0.40
LCD 26±4 25±3 0.009 24±3 0.003 24±3 0.016 0.002
HbA1c (%) LFD 7.4±2.8 0.83 7.3±3.1 0.23 7.2±2.9 0.021 7.5±3.1 0.69 0.19 0.73
LCD 7.5±2.8 7.0±2.9 0.016 7.2±3.1 0.062 7.5±2.9 0.94 0.026
HbA1c (mmol/mol) LFD 57.9±7.6 0.83 55.9±9.9 0.23 55.5±8.0 0.021 58.5±10.4 0.69 0.19 0.73
LCD 58.4±7.5 52.8±8.3 0.016 54.8±10.1 0.062 58.3±8.7 0.94 0.026
Systolic blood
pressure (mmHg)
LFD 134±11 0.73 129±13 0.078 127±12 0.022 123±10 0.005 0.007 0.73
LCD 133±13 125±16 0.053 127±13 0.085 126±14 0.195 0.13
Diastolic blood
pressure (mmHg)
LFD 74±10 0.91 74±8 0.84 68±9 0.035 70±8 0.032 0.012 0.80
LCD 74±11 71±8 0.17 71±11 0.16 71±8 0.11 0.22
Total cholesterol
(mmol/l)
LFD 4.0±0.7 0.078 4.1±0.9 0.67 4.0±0.7 0.66 3.9±0.8 0.57 0.73 0.11
LCD 4.5±1.0 4.4±1.3 0.65 4.4±0.9 0.34 4.4±1.0 0.67 0.90
LDL-cholesterol
(mmol/l)
LFD 2.2±0.4 0.043 2.2±0.7 0.84 2.2±0.6 0.91 2.0±0.7 0.16 0.43 0.13
LCD 2.7±0.9 2.5±0.9 0.37 2.5±0.7 0.10 2.4±0.8 0.066 0.34
HDL-cholesterol
(mmol/l)
LFD 1.14±0.32 0.94 1.18±0.32 0.28 1.21±0.26 0.029 1.26±0.34 0.050 0.080 0.67
LCD 1.15±0.36 1.26±0.48 0.034 1.23±0.38 0.017 1.37±0.46 <0.001 <0.001
Triacylglycerols
(mmol/l)
LFD 1.5±0.7 0.88 1.4±0.7 0.67 1.4±0.7 0.17 1.6±1.0 0.52 0.49 0.91
LCD 1.4±0.6 1.4±1.1 0.97 1.4±0.5 0.84 1.5±0.8 0.56 0.96
Total insulin
dose (E)
LFD 32±41 0.73 30±37 0.34 31±38 0.73 30±40 0.68 0.92 0.38
LCD 26±54 14±28 0.13 16±33 0.16 20±37 0.34 0.12
Metformin (mg) LFD 1,353±981 0.81 1,176±865 0.27 1,324±847 0.79 1,265±903 0.65 0.58 0.90
LCD 1,278±844 1,444±784 0.055 1,306±860 0.85 1,222±826 0.71 0.37
Glibenclamide
(mg)
LFD 0.7±2.6 0.45 0.5±1.7 0.33 0.6±1.7 0.67 0.6±1.7 0.67 0.69 1.0
LCD 1.5±3.1 0.5±1.2 0.056 0.3±0.9 0.083 0.2±0.8 0.099 0.039
Simvastatin (mg) LFD 21±17 0.64 21±17 –e 25±17 0.19 25±17 0.19 0.14 0.95
LCD 18±19 23±19 0.16 26±23 0.049 26±23 0.049 0.025
Atorvastatin (mg) LFD 1±2 0.21 1±5 0.33 1±5 0.33 1±5 0.33 0.40 0.30
LCD 3±7 3±8 0.33 3±8 0.33 3±8 0.33 0.40
LFD, n017; LCD, n018
a Between groups at baseline
b For change compared with baseline
c For change over all time points
d For change over all time points between groups
e As there were no changes in simvastatin doses, the t test is not applicable
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until the end of the trial and it was thus judged to be of little
meaning to ask participants with little intake of energy from
carbohydrates in the low-carbohydrate group at baseline
whether this was a consequence of the randomisation, which
had occurred more than 2 years earlier.
The largest changes in macronutrient intake were seen in
patients randomised to the low-carbohydrate group. Indeed,
patients in the low-fat group had the same macronutrient
composition at baseline as during the study, suggesting that
this was indeed a traditional diet and that they, according to
the diet records, had been given similar diet recommendations
earlier.
The patients following the LCD increased the percentage
of energy intake from both total and saturated fat throughout
the 24 months of the trial according to diet records, in line
with the study protocol. At 6 months, when weight reduction
was most pronounced, only the LCD group had changes in
blood lipid levels in the form of increased HDL-cholesterol.
However, during the study there had also been changes in
lipid-lowering therapy that make these findings inconclusive
regarding whether they solely depended on changes in diet. At
the end of the trial, several patients had been newly started on
lipid-lowering therapy. This is an obvious limitation of our
trial from a mechanistic point of view, but it was a conse-
quence of our efforts to limit the resources necessary for the
diets to be implemented in regular primary care, to allow the
methods to translate easily to real-life application. However,
as 3-hydroxy-3-methylglutaryl-coenzyme A reductase inhib-
itors (statins) mainly affect LDL-cholesterol levels and, as
earlier trials have also found that diets high in fat elevate
HDL-cholesterol to a greater extent than high-carbohydrate
diets in type 2 diabetes [9, 11, 16], we find it likely that the
increase in HDL-cholesterol in our trial was mainly an effect
of the change in diet.
We acknowledge that the general applicability of our
study results might be limited because of the high partici-
pation rate that was achieved. The study nurses had also
taken care of the same patients ahead of the study start and
when identifying potential participants according to inclu-
sion and exclusion criteria it cannot be excluded that, prior
to the study, they might have discharged patients judged not
to have been suitable participants for various reasons. An-
other potential explanation for the high participation rate
was that the study protocol was not very time-consuming
for the patients as it involved only four group meetings. We
also acknowledge the problems with diet records. Although
diet records with notebooks and scales can be more detailed
and precise than standardised food frequency question-
naires, results from surveys of food intake have low repro-
ducibility and, in particular, there are systematic errors in
underreporting energy intake [22]. Thus, total energy intake
might not be accurate in our study, but the lowering of
HbA1c in only the low-carbohydrate group at 6 months
and also differences in HDL-cholesterol changes at similar
weight reductions suggest that the groups did indeed change
their macronutrient intake differently in our trial.
The analyses of outcome in the participants who were
compliant with either energy intake or with the E% from fat
implied better long-term effects on weight loss than in the
total cohort analysed on an intention-to-treat basis. Al-
though this was a post-hoc analysis, and thus data should
be interpreted with caution, it was of interest to note that
HDL-cholesterol increased by 33% in patients reasonably
compliant with fat intake, which was in line with data from
Westman et al [9]. However, blood pressure levels were not
reduced in patients on the LCD at 24 months. It cannot be
excluded that salt intake increased in parallel with ingestion
of fat, as has been demonstrated in the general population
[23], leading to less favourable blood pressure levels. Un-
fortunately, we did not collect urine for determination of the
amount of sodium.
In conclusion, our findings support the use of an LCD with
20 E% from carbohydrates as an alternative to a traditional
low-fat diet, if the aim primarily is to improve glycaemic
control in type 2 diabetes. We achieved a weight loss of about
4 kg in both groups after 6 months based on group information
on three occasions and there was only one more group meet-
ing, which took place at 12 months’ study duration. However,
as in many earlier studies, compliance with the LCD was
reduced after 6 months, as judged by the increase in body
weight and according to food records, and it cannot be ruled
out that different results could have been obtained if more
effort had been made to achieve compliance with the diet
composition and reduction of energy intake.
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